text:
Serving Virginia, Maryland and Washington, D.C. | FREE CONSULTATIONS
What To Do After An Accident
Inadequate Staffing
Overmedication and Lethargy
Serious Fractures
Impaction/Bowel Blockage
Use of Restraints Causing Injury
Unexplained Injuries
Assisted Living Negligence
Nursing Home Wrongful Death
Malnutrition & Dehydration
Brain Damage and Stroke
Medical Malpractice Wrongful Death
Misdiagnosis & Failure To Diagnose
Articles/Blog
Facility Watch List
How to Pursue a Malpractice Claim
Elder Neglect Abuse – Definitions
Malpractice Statutes
Northern Virginia Surgical Error Attorney
Jeff Downey / Northern Virginia Services / Northern Virginia Surgical Error Attorney
From bowel or other organ perforations to the failure to remove sponges, clamps, and other foreign objects, surgical errors are more common than one might think. If you or a loved one has suffered an unexpected adverse outcome after a surgical procedure in Maryland, Washington, D.C. or Virginia, you many want to get a free case evaluation from an attorney at The Law Office of Jeffrey J. Downey. If you're in need of a Northern Virginia Surgical Error Attorney, make sure to call us today.
We represent clients in complex medical malpractice litigation including injuries and wrongful death resulting from:
Wrongful death due to surgery
Unnecessary surgery
Cosmetic surgery errors
Anesthesiology mistakes
Post-surgical hospital infections
C-section birth injury errors
Pre- and post-surgery medication errors
The fact that one experiences an adverse outcome does not mean the health care provider was necessarily negligent. Most cases require an expert qualified in the particular field of medicine to evaluate the case for breaches in the standard of care. Many states, including Virginia and Maryland, require expert certifications before a party may file suit against a health care provider and place caps on a recovery.
Contact Our Law Firm
If you or a loved one was injured due to a medical mistake, contact The Law Office of Jeffrey J. Downey, P.C., to discuss your case.
Free Initial Consultations | No Attorney's Fees Unless We Win Your Case
Watch List: Crofton Convalescent Center
Watch List: Brighton Gardens
District of Columbia Reexamines Contributory Negligence Principles As Applied to Scooters and E-Bikes
Watch List: Potomac Falls Health and Rehabilitation Center
Watch List: Garden House at Edenton
McLean Virginia Office
8270 Greensboro Drive, Suite 810
McLean Law Office Map & Directions
FREE INITIAL CONSULTATIONS | EMAIL US
Alexandria Virginia Office
4655 Neely Ann Court, Alexandria, VA 22310
Alexandria Law Office Map & Directions
The Law Office of Jeffrey J. Downey, P.C., provides legal advice and representation to clients in Washington, D.C., Northern Virginia (including Arlington County, Fairfax County, Prince William County and Loudoun County, as well as the cities of Alexandria, Falls Church, Arlington, Fredericksburg, Dale City, Manassas, Woodbridge, Annandale, Centreville, Chantilly, Reston, Burke and Oakton), and Southern Maryland (including Prince George's County and Montgomery County, as well as the cities of Bethesda, Wheaton, Silver Springs, Rockville, Gaithersburg and Bowie).
*AV Preeminent and BV Distinguished are certification marks of Reed Elsevier Properties Inc., used in accordance with the Martindale-Hubbell certification procedures, standards and policies. Martindale-Hubbell is the facilitator of a peer review rating process. Ratings reflect the confidential opinions of members of the Bar and the judiciary. Martindale-Hubbell ratings fall into two categories – legal ability and general ethical standards.
Required Legal Disclaimer: This web site was created for informational purposes and should not be construed to constitute legal advise or an agreement to represent you in any matter. An attorney client relationship cannot be formed by reading this web page or filling out the contact page, and will only be created through a mutual written agreement. To the extent that the rules of professional responsibility require us to designate an attorney responsible for this Web site, it is attorney Jeffrey J. Downey. Case results depend on a variety of factors that are unique to each case. Because each case is different, prior verdict results are for informational purposes only and should not be construed as a promise or guarantee of similar results.
© 2019 by The Law Office of Jeffrey J. Downey, P.C. All rights reserved. Produced by Mojo.


Top global sports goods players - Nike, Reebok and Adidas - are still in the red in India even as brands like Levis, UCB and Zara have turned profitable. While Zara has been profitable in India for at least four years, Levi's and United Colors of Benetton (UCB) despite being in the black, are dealing with accumulated losses.
German sports goods maker Puma, which has emerged as the top global lifestyle brand here in terms of revenues (Rs 878 crore) and Spanish clothing brand Zara (Rs 720 crore) are two leading global brands that do not have accumulated losses, according to regulatory filings.
Puma follows calendar year for reporting business numbers, while most of the other brands such as Benetton, Adidas and Zara follow April-to-March financial year. Adidas, with sales of around Rs 805 crore in FY15, has accumulated losses of around Rs 68 crore, while Reebok, which is owned by it, has accumulated losses of around Rs 2,198 crore with sales of around Rs 332 crore in FY15.
"The high accumulated loss situation is primarily due to issues Reebok India faced in 2012. Post that, the company has taken steps to correct its business practices and build a sustainable model based on robust fundamentals," the company said.
Nike with sales of around Rs 804 crore in FY15, has piled up accumulated losses of around Rs 541 crore, up from around Rs 439 crore in FY14, according to the US firm's latest filing with the Registrar of Companies. UCB, with sales of around Rs 719 crore, has accumulated losses of around Rs 84 crore and Levi's with sales of around Rs 634 crore has accumulated losses of around Rs 93 crore in FY15. Both companies made profits in the current year of around Rs 47 crore and Rs 11 crore respectively.
"Although we have reported accumulated losses in 2015 owing to past investments for expansion, for the past five years, we have been reporting profits, and enhanced financial health year on year," said Sundeep Chugh, CEO of Benetton India.
Sanjay Purohit, MD for South Asia (India, Sri Lanka, Nepal, Bangladesh), Levi Strauss said: "If you compare performance as per RoC filings for FY14-15 along with FY13-14, our revenues grew by 9% and operating profit grew by 184%. We have delivered an exceptional performance in the last two years."


text:
People Who Wake Up Early Are Smarter, Healthier & More Productive
By Rebecca Jane Stokes — Written on Feb 08, 2022
Photo: Dragon Images / Shutterstock
I always thought when I grew up, I would be a person who got up early.
My dad is an early riser and the dude is basically a genius. Though to be fair, my mom will sleep as long as she can as often as she can, and she's no slouch either.
RELATED: 12 Sexy Good Morning Texts To Wake Him Up Right
While recently flagellating myself over getting up at 11 am on Saturday (HELL YEAH NO KIDS) I resolved to start getting up earlier. But there was a devil on my shoulder sleepily whispering, "what's the science behind this puritanical way of thinking? Getting up early isn't going to make you a genius."
Verily, I took to my Googling machine and made some startling discoveries. I kind of don't want to share what I learned about waking up early, but you go-getters are so self-righteous anyway. But I'm a journalist, so I will.
Here's what I found about getting up early with the birds:
1. It makes you smarter.
In 2008, a study by the University of Texas found that students who self-reported as early risers earned up to a full letter grade higher than their classmates who were probably still sleeping while the questionnaires were passed out.
RELATED: The 5 Best Morning Sex Positions To Start Your Day Off With A Bang
2. It makes you happier.
The same study also found that early birds reported being happier with their lives than the night owls. To be fair, this could be because the night owls were super-pissed about being woken up before ten to answer this question.
3. It makes you healthier.
If you get up early, you can do stuff like exercise before the sun sets. The earlier you exercise, the more benefits you get all day long from that workout. Note: waking up early itself does not count as exercise. I know, I'm sad too.
4. It will make you more productive.
A study at the University of Education at Heidelberg found that early risers got more done and felt in more control over their schedules than late risers. I don't know about you, but I'm a super night owl, and while "watching all of the TV" might not sound productive, believe me, it took time and effort.
RELATED: 4 Reasons Morning Sex Is The Best Sex (For You And Your Relationship!)
5. It will give you better self-esteem.
Research indicates that those who get up before the butt crack of dawn are more likely to exhibit character traits like optimism, self-satisfaction, and social awareness.
Scatterbrained People Are Basically Geniuses, Says Psychology
The Best Time To Wake Up When You Have Depression, According To Science
36 People With The Highest IQs Of All Time
I am a proud pessimist and if you need me I'll be under my covers until the light goes away, please and thank you. I will gladly be all of the horrible things they say you are if you're not an early bird if it means I get to have just five more minutes under my covers.
Rebecca Jane Stokes is a writer and editor living in Brooklyn, New York with her cats, Batman and Margot. Her writing focuses on relationships, pop culture, and news.

redpajama_set_name: RedPajamaCommonCrawl


text:
Brenda Hillman Interview In A Few Minutes Before Later
Brenda Hillman's Resentment Box
I had the honor of conducting another interview with Brenda Hillman on December 12, 2022. The subject was her new book In A Few Minutes Before Later. It is wonderful to see a poet evolving in such a beautiful way as Brenda is, following her own "permission to be strange." I will be facilitating a deep dive into this book between January 8 and the middle of May in our online workshops. There is room in the Thursday night session, Poetics as Cosmology. Info here.
My introduction to the interview:
Bryophytes, chlorpyrifos & the protest voices are but three images in one poem by Brenda Hillman early on in her new book In a Few Minutes Before Later published by Wesleyan University Press. The L.A. Review of Books said the new book features: "a determinedly expansive poetry that includes prose, photographs, diagrams, pedigree charts, and all sorts of typographical expressionism." She draws on influences including Henri Bergson, Muriel Rukeyser, Fred Moten and Lorine Niedecker to create an idiosyncratic gesture that's ecological, activist, playful and vulnerable. There is no poet like her writing today and possibly forever and she's our Zoom guest today to talk about In a Few Minutes Before Later. Brenda, before we get into the new book, may I ask you when you gave yourself "Permission to be Strange?"
Podcast (prophets-podcast): Play in new window | Download (Duration: 1:00:30 — )
Manny Meyer on January 2, 2023 at 6:44 am
wonderful interview that came into my ears at 6am this morning…
thank you for this
Heidi Garnett on January 12, 2023 at 10:04 am
Listening to Hillman's comment on how we objectify animals and even other humans brought to mind Don McKay's book Vis a Vis. McKay calls this appropriation as us viewing animals and nature itself as objects or material. "The armchair is suddenly crouched in such defamiliarizations…its alien being." A lover reminds us of our mortality. McKay poses the question whether these appropriations are, in fact, a denial of our mortality and that we "inflict our rage for immortality on things, marooning them on static islands."
Carlton JOHNSON on January 25, 2023 at 10:03 am
I have been thoroughly enjoying the poetry from A Few Minutes Before Later. Her writings of protest and her care of environmental concerns in truly inspired. i have enjoyed reading her 'experimentations' with line breaks, punctuation and other 'conventions'. The stories in the book along with the photos make it a deep dive into what really matters in this world we all find ourselves in now.
On Irma Pineda (Isthmus Zapotec) by Wendy Call (Translator)
Our latest Cascadian Prophets podcast guest is Wendy Call. She is translator of Isthmus Zapotec poet Irma Pineda. The...
Mary Norbert Körte Interview Part 2
When I visited Mary Norbert Körte in October of 2019, we recorded interviews on consecutive days. On the second day we...


Did you know that those "age spots" are just sun damage? And did you remember that UVA rays come through car and home window glass? Put the two together and it's a recipe for spots.
Don't forget to sunscreen your hands if you're outdoors. And, if you spend a lot of time in a car, consider getting some driving gloves. If you're a golfer, try to golf both hands and put sunscreen on any exposed skin on the back of your hand by the strap of the glove. Reapply sunscreen after washing your hands if you can.


text:
European eGovernment Award Winners Announced: Outstanding Digital Public Services
Winners of the European eGovernment Awards were announced today at the Ministerial eGovernment Conference in Lisbon. The city of Amsterdam from The Netherlands, the Ministry of Government Administration and Reform of Norway, the city of Besancon from France and the portal of the Federal Government of Germany each picked up one of the prestigious awards celebrating Europe's most innovative public services. The prize for the "most inspiring good practice" went to the State Police of Italy as a result of a public vote. The winners were each presented with the European Award Trophy by Vice President Siim Kallas of the European Commission and Minister Silva Pereira of the Portuguese Presidency.
The award categories, conference themes and winners were:
For better public services for growth and jobs: Horeca1: "One-stop-shop for hotel restaurant cafe licences" submitted by the Economic Development Department, city of Amsterdam, The Netherlands. Horeca1 helps entrepreneurs and SMEs to easily find out which governmental documents they have to obtain for the seven local licences required in the city, by answering questions online and filling out a single form.
For participation and transparency empowering citizens and business to influence open government, policy-making and the way public administrations operate and deliver services: Mypage: Self-service citizen portal submitted by Norge.no, portal of the Ministry of Government Administration and Reform of Norway. Mypage offers more than 200 services for citizens. More than 200,000 users registered on the portal within its first 4 months of its operation.
For Social impact and cohesion public services: Besancon.clic submitted by the city of Besancon, France. Besancon has been recycling computers donated by firms. Once refurnished in a center for disabled workers, recipients of these computers have included primary schools, hospitals, associations, retirement homes and, since 2006, some schools in Senegal.
For Effective and efficient administration: DVDV "German Administration Services Directory" submitted by BIT the portal of the Federal Government of Germany. DVDV is a service directory supporting the interworking of online public services at a "machine to machine" level. It lists agencies and other providers with their respective services, so that queries can be executed directly by different software applications rather than requiring human intervention.
There was also a public vote to award the most inspiring good practice for creative solutions to common challenges that inspire others. OLPS "Online Police Station" submitted by the State Police of Italy. OLPS was launched by the Italian State Police in February 2006. It uses a virtual reality interface to provide general information and online assistance. Citizens can download forms, make complaints, receive advice and/or report events of an illegal nature.
Nominations for the eGovernment Awards were assessed for innovativeness and effective management, real practice results and impact, and relevance and transferability.
The Ministerial eGovernment Conference "Reaping the Benefits of eGovernment" on 19-21 September 2007 in Lisbon was jointly organized by the Portuguese Presidency of the European Council and the European Commission. Fifty-two of the most successful eGovernment applications by member states were nominated as candidates for these awards, and invited to exhibit at the conference. Over 300 documented cases of good practice in eGovernment are maintained online at the Commission's exchange site, consulted by over 15,000 visitors every month.
Quelle/Source: Government Technology, 20.09.2007


text:
Trenton Doyle Hancock
mixed media on canvas
Trenton Doyle Hancock was born in Oklahoma and is currently living and working in Houston. As the stepson of a Texas preacher, Hancock's work is largely autobiographical and based on a highly developed personal mythology. In this work, he includes a narrative that references a battle between good and evil. Hancock's paintings are characterized by cartoon-inspired faces and forms, which have elicited comparisons to the work of Philip Guston. In this work, Hancock portrays his version of the devil as a tangled mass of bones and lines with floating eyes. Hancock participated in the 2000 and 2002 Whitney Biennials, and his work is included in the permanent collections at the Dallas Museum of Art; High Museum of Art, Atlanta; Museum of Modern Art, New York; and the San Francisco Museum of Modern Art.
Estimated Retail: $25,000
Courtesy of the artist and James Cohan Gallery, New York and Shanghai
Gallery Website: www.jamescohan.com
More Catalogue Items
< PreviousJacob El Hanani
Next >Chloé Custom Handbag


text:
Facts >
Stigma 8.3.16
Stigma 6.13.13
Never-Smokers
Stanford Video
Lung Cancer FAQ
The Hummingbird
Accomplishments >
Lung Cancer License Plate
Dancing for Joan >
Dancing for Joan
Dr. Scheinberg
Radio PSA 2
Radio Appearance
Billboard 2
ajc.com
2007 - 2010 Efforts
In Memory of Joan
In Memory of Richard
The GO2 Foundation
Top Cancer Killer Ranks Low for Research Funds
This article was originally published at 4:24 pm on Tuesday, December 3, 2013 by Kathryn Roethel of the San Francisco Chronicle
When it comes to U.S. cancer research funding, deadly disease doesn't always translate into dollars. Lung cancer - the nation's top cancer killer - ranks near the bottom by many measures of funding.
Lung cancer's five-year survival rates have hovered around 15 percent for the past four decades, while survival rates for most other cancers have climbed. Ninety-nine percent of prostate cancer patients and 89 percent of breast cancer patients now live at least five years past diagnosis. Lung cancer symptoms are vague and there isn't a screening approved for the general population, so doctors often discover lung cancer in advanced stages.
Last year, the National Cancer Institute, a division of the government's National Institutes of Health, awarded breast cancer researchers nearly twice as much funding as lung cancer scientists. In the ratio of research dollars to deaths for the 10 most common types of cancer, lung cancer ranks near the bottom of the list.
One problem, according to Dr. Heather Wakelee, a thoracic oncologist at the Stanford Cancer Institute, is that most people view lung cancer as a smoker's disease that could have been prevented.
While a majority of U.S. lung cancer patients are current or former smokers, about 20 percent of women and 10 percent of men with lung cancer never smoked. If only nonsmokers' deaths were counted, lung cancer would still rank in the top 10 deadliest types of the disease. The promising news, Wakelee said, is tumors often mutate differently in nonsmokers, and new drugs are being developed to target those mutations and increase survival rates.
Here's a look at lung cancer funding, by the numbers.
The number of Americans projected to die of lung cancer in 2013. Lung cancer kills about four times more people than breast cancer and three times more than colorectal cancer, the second leading cancer killer.
$314.6 million
The amount of research dollars lung cancer received from the National Cancer Institute in 2012, making it second to breast cancer in federal funding. Breast cancer researchers received nearly twice as much.
When the amount of NCI lung cancer research funding is divided by the number lung cancer deaths, it equates to about $2,000 for each person who died last year. For breast cancer, it's more than $15,000 per death. It's about $9,000 for each prostate cancer death, and $5,000 for each colon cancer death.
The percentage of Americans with lung cancer who have never smoked, according to the Lung Cancer Foundation of America. Forty-five percent are former smokers, and the remaining 40 percent currently smoke.
The Bonnie J. Addario Lung Cancer Foundation presents: "The Next Decade in Lung Cancer"
The brightest minds in research, academics and advocacy unite at the Lung Cancer Living Room.
Published on November 5, 2013 by The Bonnie J. Addario Lung Cancer Foundation
SAN CARLOS, CA, Nov. 5, 2013 /PRNewswire-USNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation (ALCF) is proud to present The Next Decade in Lung Cancer, a three-part series of the Lung Cancer Living Room, the nation's premiere live-streamed support group for patients, family and friends.
"We are asking the big question. What will it take to make lung cancer a chronically managed disease in the next 10 years?" said Bonnie J. Addario, lung cancer survivor and founder of the ALCF. "The Next Decade in Lung Cancer offers a glimpse into the future from the perspective of researchers, advocates and most importantly patients."
The three-part series will unite industry leaders in medicine, research and technology who will discuss the latest advancements and breakthroughs in lung cancer. Advocacy and policy agencies and foundations will also discuss access, information, education and needed legislative changes.
The series, which will take place over the next three months, kicks off on November 10, 2013 at 2 p.m. (PST). Guests who attend the Living Room in-person will have the opportunity to network with other patients and with the guest speakers listed below. Online guests can also participate through the live stream, asking questions and sending comments via a live chat function. The session also airs at a later date locally on Peninsula TV.
Guest Speakers:
Larry Heifetz, MD, FACP Gene Upshaw Memorial Tahoe Forrest Cancer Center (Moderator)
Andrew Allan MD, PhD - CMO/EVP Clinical - Pre-Clinical Development – Clovis Oncology
David Jablons, MD, University of California San Francisco Medical Center
Ita Laird-Offringa, PhD, University of Southern California Medical Center
Harvey Pass, MD, New York University Cancer Center - Langone Medical Center
For more information about the full series, please visit the ALCF website.
The ALCF regularly hosts the Living Room on the third Tuesday of every month and the program is live-streamed online. It is the nation's premier lung cancer support group for lung cancer patients and their families, offering expert opinion and advice not found anywhere else. Visit www.ustream.com and select the Lung Cancer Living Room Support Group channel to see the video archive, including full length videos and 20-minute condensed highlighted versions, available the week after the group meets.
The patient empowerment educational series is made possible through funding partners: Biodesix, Bristol-Myers Squibb, Celgene, Genentech and The Safeway Foundation.
About The Bonnie J. Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change. The ALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised more than $10 million for lung cancer research and patient services.
Research Study Aims to Understand Inherited Lung Cancer Gene
INHERIT EGFR Study Expands to Second Site
SAN CARLOS, Calif., Oct. 30, 2013 /PRNewswire-USNewswire/ -- A new research study, funded by the Bonnie J. Addario Lung Cancer Foundation (ALCF), is aiming to understand how an inherited gene in some lung cancer patients could serve as an early detection screening for family members.
"We're hoping this study provides new insight for methods to screen for lung cancer in people who might not have otherwise qualified for screening: the family members of lung cancer patients," said Bonnie J. Addario, lung cancer survivor and founder of the ALCF. "And we also hope to show that lung cancer doesn't just affect people who smoke."
The INHERIT (Investigating Hereditary Risk from T790M) research study, facilitated by the Addario Lung Cancer Medical Institute (ALCMI), is the first to apply inherited familial genetics – widely used to assess risk for breast and colon cancer – to provide insight into lung cancer. Dr. Geoffrey Oxnard and a team of physicians at Dana-Farber/Brigham and Women's Cancer Center in Boston, MA are leading the INHERIT study to understand whether the presence of the T790M gene mutation in lung cancers is associated with an inherited gene alteration. Oxnard's team will also examine whether having the inherited form of T790M raises the risk of lung cancer in patients and families. The ALCMI study was launched at Dana-Farber and has now expanded to include Vanderbilt-Ingram Cancer Center in Nashville, Tenn. No travel is required to participate.
"This is the first time we are using cancer genetics to offer insight into inherited familial genetics. For breast cancer or colon cancer, it is patients with a family history that get evaluated for inherited mutations in cancer risk genes," said Geoffrey Oxnard, MD, the lead researcher on the study. "For lung cancer, we propose that it is patients with specific genetic subtypes of lung cancer, those carrying the EGFR T790M mutation, that need to be evaluated for an inherited mutation in their family."
Ultimately, the study aims to identify individuals and families who may have an increased risk of developing lung cancer so they can work with their physicians to reduce and manage that risk. Understanding lung cancer's underlying biology in high-risk families could also provide unique insight into why the disease develops and determine whether "germline" (inherited) factors may partly explain lung cancer in individuals without apparent carcinogenic association.
"We are funding this study because of our patient first commitment," Addario said, "and with the hope to raise awareness that the risk for lung cancer exists regardless of smoking history. In 2013 alone, 34,000 people who never smoked will be diagnosed with lung cancer. That population of cancer patients, isolated, would represent the seventh leading cancer in the U.S."
The INHERIT study is offered through Dana-Farber/Harvard Cancer Center, Vanderbilt-Ingram Cancer Center, and soon at other ALCMI member institutions in the United States and Europe. It is led by Geoffrey Oxnard, MD at Dana-Farber/Brigham and Women's Cancer Center. Dana-Farber and Vanderbilt are National Cancer Institute-designated Comprehensive Cancer Centers.
This study is also funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO).
View video on T790 mutation research at www.dana-farber.org/T790Mstudy
Contact Dr. Oxnard at 617-632-6049, dfcifamilialT790M@dfci.harvard.edu
About the Addario Lung Cancer Medical Institute
The Addario Lung Cancer Medical Institute (ALCMI) is a patient-founded, patient-focused 501c(3) non-profit research consortium established in 2008 that directly facilitates basic and clinical research to accelerate the discovery and delivery of advancements to patients. By bringing together a world-class team of scientists and clinicians from over 20 academic and community medical centers in the U.S. and Europe, ALCMI has rapidly established a critical mass of expertise and dedicated research infrastructures linked together through centrally coordinated research.
SOURCE Bonnie J. Addario Lung Cancer Foundation
Read more: http://www.digitaljournal.com/pr/1556776#ixzz2jK46ND7q
An oldie, but a goodie. Please read.
The following was originally published at DukeHealth.org by Dr. Thomas A. D'Amico on June 21st, 2011. Thomas A. D'Amico, MD, is a professor of surgery and director of the Duke Cancer Institute's lung cancer program. He was elected chair of the National Comprehensive Cancer Network board of directors in 2010.
Lung Cancer: Is "The Blame Game" Hurting our Progress?
Thomas A. D'Amico, MD
As a thoracic surgeon, I operate on lung cancer patients every day. We discuss life-and-death issues regarding their surgeries, but we don't usually talk about how they feel about their disease.
At a recent lung cancer advocacy event, I had the opportunity to hear one of my patients tell her story. A former Division I soccer player for East Carolina University, 24-year-old Taylor Bell was diagnosed with lung cancer two weeks after her 21st birthday. She puts a very different face on lung cancer than most people expect.
She's very grateful for her survival, but she says that, even when she's talking to survivors of other types of cancer -- to anyone, really -- when she tells people she has had lung cancer, inevitably everyone asks the same thing: "Did you smoke?"
Her point of view is, "Why is that the most important thing you want to know about me?" It's offensive to her because, number one, she didn't smoke, and number two, what if she did? Would that mean that she deserved the disease?
Assigning Blame for Lung Cancer
That is the underlying assumption when many people think about lung cancer: In an international survey commissioned in 2010 by the Global Lung Cancer Coalition, 22 percent of U.S. respondents admitted they feel less sympathy for lung cancer patients than for patients with other types of cancer, because of the link to smoking.
The reality is that 15 to 20 percent of folks who get lung cancer have no personal firsthand experience with tobacco. Some, like Taylor Bell, are complete non-smokers. Some have been exposed to secondhand smoke, which certainly is not their fault.
If you counted just deaths from lung cancer among nonsmokers, lung cancer would still be the sixth leading cause of cancer-related deaths in the United States.
But no one should be blamed for getting cancer, regardless of their smoking history. Most smokers first start the habit as teenagers, and by adulthood it becomes entrenched; nicotine addiction is among the hardest to overcome.
The real issue is not the smoker who develops cancer; it's how we as a society assign blame for disease. If we are to measure our sympathies for the ill by the behaviors that may have contributed to their illness, what about the patients with debilitating heart disease who have led high-stress, low-exercise lifestyles, or people with type 2 diabetes who had poor eating habits?
What about the smokers who didn't develop lung cancer but developed breast cancer, heart disease, or stroke?
Would you have more sympathy for a smoker with lung cancer if you knew he had grown up with little education about the dangers of smoking?
What about if the individual had a strong genetic predisposition to nicotine addiction?
Stigma Slows Progress in Fight Against Lung Cancer
The truth is, it's rare that we can draw a straight line from a person's disease to their lifestyle choices, and applying moral judgments to the ill is not only a waste of energy, but also a slippery moral slope.
I believe the public-health campaign against smoking and tobacco use has had unintended consequences: not only stigma for the victims of diseases associated with smoking, but actually slowing our progress in the fight against those diseases. And that is something we need to pay attention to.
The fact is that lung cancer is the most important cancer disease in our country, and indeed among all developed countries, in terms of its impact. In 2010, lung cancer caused 157,300 deaths in the United States, more than breast, prostate, and colon cancer combined, according to estimates from the American Cancer Society.
In 2006, the most recent year for which we have estimates, we spent $10.3 billion in care for lung cancer patients, and the estimated loss of economic productivity due to lung cancer is $36.1 billion -- far higher than the next-highest figure (which is breast cancer, at a $12.1-billion loss).
The burden of this disease to us as a society should be, in itself, enough to compel us to do everything we can to improve diagnosis and treatment. Yet lung cancer receives much less research funding than other types of cancer that cause fewer deaths.
The stigma associated with lung cancer definitely takes its toll on survivors personally, and it's possible that it also affects research funding for the disease. Using the most recent available data on National Cancer Institute research funding, lung cancer received only $1,875 per death, compared to $17,028 per breast cancer death, $10,638 per prostate cancer death, and $6,008 per colorectal cancer death.
It's impossible to read the minds of people who make decisions regarding funding for lung cancer research, but I think funding disparities can be attributed partly to a combination of the smoking stigma and ageism. If a 73-year-old person has a life-threatening disease, that's not perceived as being as important to society as a disease that affects younger people. And an older patient population also means less patient advocacy.
The fight against breast cancer, for example, has been promoted successfully because many young women who are survivors have their life to give to raising awareness. The cure rate for lung cancer is much lower than for breast cancer. So there are fewer advocates.
Need for New Screening Methods and Biologic Therapies
There is a need for greater research funding to advance two priorities that could make a significant difference for patients with lung cancer -- perfection of screening methods to catch more cases in the early stages, and stepped-up evaluation of biologic therapies, which can be equally as effective or more effective than chemotherapy without the overall toxicity.
Improved screening is an urgent need. Today, only about 20 percent of lung-cancer cases are caught at stage one. If we could increase that to 40 percent, we would improve survival dramatically.
Spiral computed tomography (CT) scan screening is a promising technique that's being tested for patients known to be at high risk, but as a widespread tool, even CT has a drawback: the high chance of false positives.
Your CT scan might show a little nodule, but that does not necessarily mean you have lung cancer, and follow-up testing for lung cancer is invasive: if you have a positive screening for a mammography, you get a needle biopsy, but a positive screen from a CT scan might lead to a surgery.
We would like to be able to determine your true cancer status without having to do additional CT screens on you for the next five years or subjecting you to an unnecessary lung biopsy.
A line of research that holds much promise is perfecting a method for combining CT scans with a serum or urine test that detects a protein or other biomarker.
Even if we improve diagnosis, we'll always have people who present with advanced disease, and the cure rate for those people is, frankly, dismal. One way to improve that rate is with better targeting of biologic therapies.
Industry is producing these agents faster than we can test them. We need to put more effort into testing and enhancing these agents -- which could improve treatment for others cancers as well. For instance, Avastin (bevacizumab) is now known to be successful against lung cancer, but it wasn't originally conceived as a lung cancer agent.
To carry out these research priorities, we must erase the stigma that accompanies lung cancer and give the disease the full research support that its sufferers and their families deserve.
In the meantime, we will count on survivors such as Taylor Bell, who handles the smoking question with grace. After she tells people that no, she never smoked, the second question usually is: "Well, how did you get it?" Her response: "Why does anyone get cancer?"
More #Research Needs to Be Done On Treatment For #LungCancer Among Non-Smoking #Women
This story originally published by Sam Goodwin on HGNG.com on 6/26/13.
The International Association for the Study of Lung Cancer (IASLC) finds that much more research needs to be done on treatment given to non-smoking women for lung cancer.
An estimated 516,000 women worldwide are affected by lung cancer and 100,000 of these women are from the United States. Up until now, women with lung cancer have been given the same treatment as men. However, numerous studies have highlighted different characteristics of lung cancer in women. Hence, there is a need for more research to be done on lung cancer treatment given to women, especially those who don't smoke, states the International Association for the Study of Lung Cancer (IASLC).
Researchers from the University of Toulouse III in France looked into the clinical, pathological and biological characteristics of lung cancer in 140 women. They found that 63 participants had never smoked in their lives while 77 were either former or current smokers. Researchers compared the findings of both groups and found differential genetic alteration repartition in women according to their tobacco status.
Around 50.8 percent of women who had never smoked displayed an EGFR mutation while only 10.4 percent of current/former smokers showed the same mutation. However, 33.8% of current/former smokers showed K-Ras mutation while only 9.5 percent of women who had never smoked showed this form of mutation. The researchers also observed a higher percentage of estrogen receptors (ER) α expression in patients who never smoked when compared with smokers.
This led researchers to conclude that lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor (ER) over expression.
"These findings underline the possibility of treatment for women who have never smoked with drugs to target hormonal factors, genetic abnormalities, or both," the authors say.
The study is published in the July issue of the Journal of Thoracic Oncology.
#LungCancer Study Looking for Participants
Have You Had Lung Cancer?
Are You a Never-Smoker (someone who has smoked 100 or fewer cigarettes in their lifetime)?
Are You Willing to Share Your Story?
If you answered "yes,you may be eligible to participate in a study by a researcher at Capella University – your experience matters! Participation in this study involves a one-time interview, either in- person, by webcam or, if necessary, by telephone. A $10 gift card or a $10 donation to any lung cancer organization will be provided as compensation for your time.
Please contact: Rachael at RBrandt@capellauniversity.edu for more information.
We are extremely proud to be an affiliate of the Bonnie J. Addario #LungCancer Foundation @End_Lung_Cancer
Click on image below for a larger view.
Guide for #LungCancer Gene Tests Published
Originally published at medpagetoday.com by Charles Bankhead, Staff Writer, MedPage Today on April 05, 2013.
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner
All patients with advanced lung adenocarcinoma should undergo testing forEGFR and ALK mutations to determine their eligibility for targeted therapies, according to a jointly developed guideline from three organizations.
Patients should undergo EGFR testing at diagnosis of advanced disease or at recurrence or progression if they were not tested at earlier disease stages. ALKrearrangement testing is suggested by the International Association for the Study of Lung Cancer, the College of American Pathologists, and the Association for Molecular Pathology.
Patients should not be excluded from testing because of smoking status or clinical characteristics, the guideline authors said in an article published online in the Journal of Thoracic Oncology.
"It was recognized by each of these three organizations that there was a gap in knowledge, a gap in communication, and variance around the world in how this testing ought to be done," first author Neil I. Lindeman, MD, a pathologist at Brigham & Women's Hospital in Boston, said in video statement.
"We decided collectively ... that these three voices should come together in order to make a consensus guideline."
The consensus opinion of the guideline panel is that EGFR and ALK testing should be encouraged for patients with stage I, II, or III disease at diagnosis.
EGFR testing should have priority over all other genes, followed by ALK.
"Any oncologist should be able to provide this testing and should do this testing to give their patients optimal care," Gregory Riely, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York city, said in the video.
"With a proper biomarker, I can tell patients that they have a 70% to 80% chance of responding to a treatment rather than saying that they have a 1 in 10 chance of responding to treatment," he added.
Other points made in the guideline include:
Primary and metastatic lesions are equally suitable for testin
Test results should be available within 10 working days and labs that cannot keep that turnaround schedule should take steps to keep the schedule -- either in-house or at a reference lab (consensus)
KRAS testing should not be used as the sole determinant of a patient's eligibility for anti-EGFR therapy
Specimens from patients with acquired resistance to EGFR inhibitors can be tested for the secondary EGFR T790M mutation with as few as 5% of specimen cells
Reverse transcriptase polymerase chain reaction is not recommended as an alternative to fluorescence in situ hybridization assay for selecting patients for ALK inhibitor therapy
In the setting of fully excised lung cancer specimens, EGFR and ALK testing is not recommended in lung cancers that lack any adenocarcinoma component, such as "pure" squamous cell carcinomas, "pure" small cell carcinomas, or large cell carcinomas lacking any immunohistochemistry (IHC) evidence of adenocarcinoma differentiation.
The guideline addresses a variety of other issues related to testing techniques and processes, quality control, testing for secondary mutations and for other genes, and reporting results.
The broad recommendations for testing and the guideline's emphasis on urgency in obtaining test results reflect practices already in place at leading cancer centers, according to Edward Kim, MD, of Carolinas HealthCare System's Levine Cancer Institute in Charlotte, N.C.
"Testing should be based on type of patient (i.e. histology) and not clinical characteristics (i.e. smoking status or ethnicity)," said Kim, who was not involved in writing the guideline. "Both tests (EGFR and ALK) are recommended to be ordered at diagnosis, which is our current practice at Levine Cancer Institute.
"Although 'within 2 weeks' for results is recommended, I hope that the turnaround time can be shortened in the near future. Patients with lung cancer are anxious to begin therapy, and longer delays will preclude the use of these molecular agents in the front-line setting."
The guideline authors disclosed relationships with Novartis, Millennium, Arqule/Daiichi Sankyo, NanoString, Genzyme, Infinity, Sequenom, Remedica Medical Education, Abbott, Existence Genetics, CymoGen Dx, Applied Spectral Imaging, Parteq-Queen's Commercialization Office, Merck, Eli Lilly, Pfizer, OSI/Genentech/Roche, AstraZeneca, Boehringer Ingelheim, Amgen, GlaxoSmithKline, Bristol-Myers Squibb, and sanofi-aventis. Several authors disclosed royalties related to publications and fees received as expert witnesses.
Primary source: Journal of Thoracic Oncology
Source reference: Lindeman NI et al. "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" J Thorac Oncol 2013; DOI: 10.1097/JTO.0bO13ee318290868f.
IBM Supercomputer Takes on New Role in Health Arena
Originally published by Christina DesMarais at PCWorld.com on Feb. 2013.
IBM's Watson supercomputer has gone from game show king to doctor's office helper.
You may recall the epic man vs. machine battle two years ago in which the supercomputer beat former champions on the show Jeopardy.
Well, now there's a Watson tablet and computer app doctors can use to help treat lung cancer and another for health insurance companies to figure out which claims to pay, reports The Associated Press.
For the cancer program, Watson analyzed 1,500 lung cancer cases from medical records, plus millions of pages of medical text. It also is able to learn when corrected for generating a wrong answer. Armed with all this data, Watson will suggest to doctors which treatments will most likely succeed, prioritized by its level of confidence in them.
The Maine Center for Cancer Medicine and WestMed in New York's Westchester County will both be using the lung cancer app by March.
Health insurer WellPoint, which actually will be selling both applications as part of an agreement with IBM, is already using the Watson app in Indiana, Kentucky, Ohio and Wisconsin to sift through insurance claims and determine which ones to authorize.
Since Watson's victory on Jeopardy, IBM says the supercomputer's performance has increased by 240 percent and been used to analyze finance and health care data as well as in a university setting to research big data, analytics and cognitive computing.
The company also is moving some of its underlying technologies from the supercomputer into new entry-level servers used by SMBs. IBM's recently announced Power Express servers will integrate some hardware and software elements derived from Watson.
Expect to hear more about Watson—IBM says its use "will be expanding to production-level deployments in new use cases and industries going forward."
Check out this two-minute video, in which doctors talk about how Watson will be used to determine treatments for lung cancer:
Lung Cancer Harder to Diagnose in Younger Patients
This article was originally published at About.com on January 10th, 2013 by Lynne Eldridge, MD.
Studies have shown that when it comes to breast cancer, older women are more likely to be diagnosed with advanced stages of the disease.
Not so with lung cancer - at least in recent studies in Denmark and England. Instead, it seems the slogan reads "early age later stage."
Researchers in Denmark set out to evaluate the stage of lung cancer at which different age groups are diagnosed. Looking at people aged 65-69, those aged 70 to 74 were 18% less likely to be diagnosed with late stage disease. The trend continued on: Those aged 75 to 79 were 26% less likely, 80 to 84 were 27% less likely, and those over 85, 34% less likely to have a diagnosis of late disease. Since the stage at diagnosis makes a tremendous difference in long-term survival from lung cancer, this is something to stand up and take note of.
Why would younger people be less likely to diagnosed with lung cancer until it's reached the later stages of the disease? Or to ask the question in another way: Why does age seem to have a protective effect against late stage lung cancer diagnosis? Possibilities shared with me by Georogios Lyratzopoulous MD, one of the investigators in another study in England demonstating "early age later stage" include:
There may be more "opportunistic" diagnosis among the older patients. This means that since older patients have more medical conditions, they are more likely to have their lung cancers "accidentally" diagnosed when a scan is done for some other reason.
Young people may tolerate lung cancer symptoms more resiliently. This means that younger people may be able to "get by" or ignore lung cancer symptoms such as shortness of breath longer before they consult a doctor.
My own speculation was that perhaps older people are more familiar with the symptoms that could be lung cancer by virtue of having had friends and acquaintances who have had lung cancer.
The conclusion based on these findings is that efforts to diagnose lung cancer early need to be tailored to different age groups. The stage of a lung cancer at the time of diagnosis can have a huge impact on younger patients with lung cancer. In the study above from Denmark, only 17% of the cancers were diagnosed at stage 1 and stage 2. To tailor the diagnostic process for different age groups, we need to focus on more diagnostic research instead of just treatment research.
Dalton, S. et al. Socioeconomic position, stage of lung cancer and time between referral and diagnosis in Denmark, 2001-2008. British Journal of Cancer. 2011. 105(7):1042-8.
Lyratzopoulos, G. et al. Variation in advanced stage at diagnosis of lung cancer female breast cancer in an English Region 2006-2009. British Journal of Cancer. 2012. 106(6):1068-75.
Addario
Alcmi
Bjalcf
For Joan
Jogging For Joan
Lung Cancer Awareness Month
Joan Gaeta: 9/7/38 - 7/17/07
gaetafund@gmail.com


text:
Војни адвокати је Америчка правна драма са нагласком на војни жанр коју је створио Доналд П. Белисарио. Због лоше гледаности НБЦ је укинуо серију после прве сезоне, а противничка мрежа ЦБС је покренула другу сезону као међусезону 1997. године. Након што се гледаност побољшала ЦБС је серију продуживао још осам пута. Из серије "Војни адвокати" је настала серија "МЗИС", а из ње "МЗИС: Лос Анђелес" и "МЗИС: Нови Орлеанс".

Серија САГ броји 10 сезона и 227 епизода.

Преглед

Епизоде

1. сезона (1995-96)

Дејвид Џејмс Елиот, Андреа Паркер и Тери О'Квин улазе у главну поставу у епизоди "Нови живот (1. део)". Андреа Паркер и Тери О'Квин напуштају главну поставу у епизоди "Нови живот (2. део)", а њу је заменила Трејси Нидам у остатку сезоне. Андреа Паркер се касније епизодно појавила у епизодама "Бекство из затвора" и "АРЕС", док се Тери О'Квин епизодно појавио у епизоди "Одбрамбена акција".
{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#629290;"| Бр. усерији
! style="background:#629290;"| Бр. усезони
! style="background:#629290;"| Наслов
! style="background:#629290;"| Редитељ
! style="background:#629290;"| Сценариста
! style="background:#629290;"| Премијерно емитовање
|-

|}

2. сезона (1997)

Кетрин Бел је заменила Трејси Нидам у епизоди "Ми људи". Патрик Лаборто и Џон М. Џексон, који су се појављивали епизодно у претходној сезони, су унапређени у главну поставу.
{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#474206;"| Бр. усерији
! style="background:#474206;"| Бр. усезони
! style="background:#474206;"| Наслов
! style="background:#474206;"| Редитељ
! style="background:#474206;"| Сценариста
! style="background:#474206;"| Премијерно емитовање
|-

|}

3. сезона (1997-98)

{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#737372;"| Бр. усерији
! style="background:#737372;"| Бр. усезони
! style="background:#737372;"| Наслов
! style="background:#737372;"| Редитељ
! style="background:#737372;"| Сценарио
! style="background:#737372;"| Премијерно емитовање
|-

|}

4. сезона (1998-99)

{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#0E826F;"| Бр. усерији
! style="background:#0E826F;"| Бр. усезони
! style="background:#0E826F;"| Наслов
! style="background:#0E826F;"| Редитељ
! style="background:#0E826F;"| Сценариста
! style="background:#0E826F;"| Премијерно емитовање
|-

|}

5. сезона (1999-00)

{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#6F7582;"| Бр. усерији
! style="background:#6F7582;"| Бр. усезони
! style="background:#6F7582;"| Наслов
! style="background:#6F7582;"| Редитељ
! style="background:#6F7582;"| Сценариста
! style="background:#6F7582;"| Премијерно емитовање
|-

|}

6. сезона (2000-01)

{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#C26B13;"| Бр. усерији
! style="background:#C26B13;"| Бр. усезони
! style="background:#C26B13;"| Наслов
! style="background:#C26B13;"| Редитељ
! style="background:#C26B13;"| Сценариста
! style="background:#C26B13;"| Премијерно емитовање
|-

|}

7. сезона (2001-02)

{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#294D73;"| Бр. усерији
! style="background:#294D73;"| Бр. усезони
! style="background:#294D73;"| Наслов
! style="background:#294D73;"| Редитељ
! style="background:#294D73;"| Сценариста
! style="background:#294D73;"| Премијерно емитовање
|-

|}

8. сезона (2002-03)

{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#7A5063;"| Бр. усерији
! style="background:#7A5063;"| Бр. усезони
! style="background:#7A5063;"| Наслов
! style="background:#7A5063;"| Редитељ
! style="background:#7A5063;"| Сценариста
! style="background:#7A5063;"| Премијерно емитовање
|-

|}

9. сезона (2003-04)

Џон М. Џексон је напустио главну поставу на крају сезоне.
{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#B6B8AE;"| Бр. усерији
! style="background:#B6B8AE;"| Бр. усезони
! style="background:#B6B8AE;"| Наслов
! style="background:#B6B8AE;"| Редитељ
! style="background:#B6B8AE;"| Сценариста
! style="background:#B6B8AE;"| Премијерно емитовање
|-

|}

10. сезона (2004-05)

Скот Лоренс је заменио Џона М. Џексона у епизоди "Пад и одлазак (2. део)". Зои Меклилан, која се епизодно појављивала у претходне три сезоне је унапређена у главну поставу.
{| class="wikitable plainrowheaders"  style="width:100%; background:#fff;"
|- style="color:white"
! style="background:#6A8B9C;"| Бр. усерији
! style="background:#6A8B9C;"| Бр. усезони
! style="background:#6A8B9C;"| Наслов
! style="background:#6A8B9C;"| Редитељ
! style="background:#6A8B9C;"| Сценариста
! style="background:#6A8B9C;"| Премијерно емитовање
|-

|}

Извори

Војни адвокати

redpajama_set_name: RedPajamaWikipedia


text:
ICR Announces Addition of Steve Parish and Lee Stettner as Managing Directors and Co-Heads of Capital Markets
New Senior Team Members Bring More than 60 Years of Combined Experience and Advisory Roles on Hundreds of Transactions
NEW YORK – December 4, 2019 – ICR, a leading strategic communications and advisory firm, announced today that Steve Parish and Lee Stettner will be joining the firm as Managing Directors focused on capital markets advisory. The new senior team members, who bring more than 60 years of combined experience as advisors on hundreds of transactions, will report to firm CEO, Tom Ryan, and President, Don Duffy.
Mr. Parish and Mr. Stettner will also serve as Co-Heads of Capital Markets for ICR's broker-dealer affiliate, ICR Capital. Their addition further enhances the existing ICR Capital franchise. ICR Capital provides corporate management teams and financial sponsors with the independent objective advice and expertise they need to execute a wide range of financial transactions, including IPOs, follow-on offerings, block trades and alternative capital raising transactions."
Mr. Ryan and Mr. Duffy stated, "Steve and Lee possess tremendous capital markets advisory experience and their addition to ICR Capital dramatically accelerates our progress toward developing the leading transaction advisory business in North America. We believe the combination of our existing and new capital markets advisory expertise with ICR's deep industry sector expertise – which is critical to properly advising on any transaction – results in a truly unique and compelling offering. The addition of Lee and Steve is a powerful endorsement of the ICR Capital platform and adds to the significant momentum we have enjoyed over the past 18 months."
Mr. Parish and Mr. Stettner added, "The transaction advisory business in North America has evolved substantially over the past several years. Issuers and financial sponsors are increasingly looking beyond process management for a more robust and strategic level of insight that includes extensive knowledge of their sector, business model and historical trends. We believe the ICR platform is ideally suited for this next phase of evolution in the business and we could not be more excited to join this team. In addition to being able to combine deep sector knowledge from at least 20 sector specialist groups and across more than 750 clients, we can now also incorporate fully-integrated communications support that includes investor relations, public relations, media and presentation coaching, crisis communications, social and digital media and governance advisory."
Steve Parish has worked in the capital markets for more than thirty years, most recently as a Managing Director for Solebury Capital, where he spent seven years advising issuers and financial sponsors on a broad range of transactions. He began his career at Bear Stearns and remained at the firm for almost twenty five years, serving as Senior Managing Director where he was responsible for the structuring, marketing and execution of hundreds of equity and equity-linked transactions for issuers. He was the Global Head of the Equity Transactions Group and served on a number of committees, including the Commitment Committee and Equity Sub-Committee. He had oversight responsibilities for all types of offerings, including IPOs, follow-ons, 144A placements, convertible securities, and block trades. Steve received a BA in History from Tulane University and an MBA in Finance from New York University Stern School of Business.
Lee Stettner has worked in the capital markets for thirty years in a variety of senior roles in both equity capital markets and corporate finance. Since 2014, Lee has been a Managing Director at Solebury Capital. Prior to that, he was Managing Director in Equity Capital Markets for J.P. Morgan where he was also on the firm's Equity Underwriting Commitment Committee. Before joining J.P. Morgan, Lee was a Senior Managing Director and Global Head of Equity Capital Markets at Bear Stearns and from 2004-2007, he was a Managing Director at Deutsche Bank where he was Head of Healthcare Investment Banking and Equity Capital Markets Group. Lee was also a senior banker at Morgan Stanley and Credit Suisse. Lee graduated with a BA in Economics from Hamilton College and an MBA from the Wharton School of Business of the University of Pennsylvania.
About ICR
Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm's highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 750 clients in approximately 20 industries. ICR's healthcare practice operates under the Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Francisco, San Diego and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.
About ICR Capital
ICR Capital, member FINRA/SIPC, a registered broker-dealer affiliate of ICR, provides transaction advisory services related to IPO execution as well as follow-on and convertible notes offerings, equity and debt capital raises and block trades. The firm provides independent advice on all aspects of the transaction process to help clients make better informed decisions. ICR Capital's advisory expertise in combination with ICR's industry leading communications capabilities helps clients achieve their transaction objectives, while establishing a foundation to maximize long-term equity value. Learn more at www. icrcapital.com.
Brian Ruby
brian.ruby@icrinc.com


text:
Q: jQuery Accordion parent link I do want to be clickable to its link the parent menu after it show the sub menu,how can it this be done below are my codes
My HTML

                Menu 1 1

Menu 1 Sub

                Menu 2

Menu 2 Sub 1

Menu 2 Sub 2

My CSS
ul#menu, ul#menu ul {
  list-style-type:none;
  margin: 0;
  padding: 0;
  width:220px;
}

ul#menu a { font:bold 12px Arial, Helvetica, sans-serif;
  display: block;
  text-decoration: none;
}

ul#menu li {
  margin-top: 1px;
}

ul#menu li a {
  background: #1c3f94;
  color: #fff;
  padding: 0.5em;
}

ul#menu li a:hover {
  background: #000;
}

ul#menu li ul li a {
  background: #ccc;
  color: #000;
  padding-left: 20px;
}

ul#menu li ul li a:hover {
  background: #aaa;
  border-left: 5px #000 solid;
  padding-left: 15px;
}

My JS
function initMenu() {
  $('#menu ul').hide();
  $('#menu ul:first').show();
  $('#menu li a').click(
    function() {
      var checkElement = $(this).next();
      if((checkElement.is('ul')) && (checkElement.is(':visible'))) {
        return false;
        }
      if((checkElement.is('ul')) && (!checkElement.is(':visible'))) {
        $('#menu ul:visible').slideUp('normal');
        checkElement.slideDown('normal');
        return false;
        }
      }
    );
  }
$(document).ready(function() {initMenu();});

LIVE DEMO

A: Don't return false when the first condition is true:
function initMenu() {
    $('#menu ul').hide();
    $('#menu ul:first').show();
    $('#menu li a').click(function () {
        var checkElement = $(this).next();
        if ((checkElement.is('ul')) && (checkElement.is(':visible'))) {
            return true;
        }
        if ((checkElement.is('ul')) && (!checkElement.is(':visible'))) {
            $('#menu ul:visible').slideUp('normal');
            checkElement.slideDown('normal');
            return false;
        }
    });
}

redpajama_set_name: RedPajamaStackExchange


Designed to be as comfortable and unobtrusive as possible, the AirFit P10 is also 50% lighter than our previous nasal pillows mask.1 The revolutionary new flexi-tube is ultra light and highly durable, letting you move around freely without compromising the mask's seal.
•Easy to use. The AirFit P10's minimalist three-piece design makes assembly, fitting and cleaning a breeze.
•Easy to assemble. Key-clip nasal pillows feature color-coded sizing and left/right-orientation for fast and easy fitting. The mask easily slips on and off without any extra steps.
•Comfortable. The mask seals on contact, with trampoline action that lets you move around comfortably without compromising the mask's seal.
This best nasal pillow I have used. I have tried at least 4 other brands and find this the lightest, best fitting and most comfortable of all. I cannot speak for the durability as of yet, but seems to be holding up well after 6 weeks. Agree with other reviews siting air exhaust being well dissipated.
The P-10 nasal pillows fit perfect. No air leakage and very comfortable.
It was exactly as expected. It worked perfectly. The only odd thing is that was marked "not for resale" on the head strap. This is the best nasal mask design I've ever used. It hardly ever slips, when it does it doesn't lead to burns, on your nose, and the nasal pillow doesn't show fatigue, even near end of use.
Heard good things about the P10 and am happy with it during the 1st week. Low impact/less instrusive than prior nasal pillow mask. Like that the exhaust air coming from the mask is dissipated and nearly undetectable. My other one blows it out with more concentrated force and can be annoying.


text:
Eine endlich erzeugte Gruppe ist ein Objekt aus dem mathematischen Teilgebiet der abstrakten Algebra. Es handelt sich um einen Spezialfall einer Gruppe.

Definition
Eine Gruppe  heißt endlich erzeugt (oder auch: endlich erzeugbar), falls es eine endliche Teilmenge  gibt, die  erzeugt. Dies bedeutet, dass  die kleinste Untergruppe von  ist, die  enthält. Die Teilmenge  nennt man Erzeugendensystem von .

Bemerkungen
 Mit  notiert man oftmals die von  erzeugte Gruppe. Das Erzeugendensystem einer endlich erzeugten Gruppe ist jedoch nicht eindeutig.
 In der Algebra betrachtet man insbesondere endlich erzeugte abelsche Gruppen, da man diese recht einfach klassifizieren kann.
 Die endlichen Gruppen sind insbesondere endlich erzeugt, die Endlichkeit der Gruppe ist hinreichend für ihre endliche Erzeugbarkeit, aber nicht notwendig.
 Notwendig für die endliche Erzeugbarkeit ist, dass die Gruppe eine abzählbare Menge ist. Dies ist aber nicht hinreichend.

Beispiele und Gegenbeispiele
 Die ganzen Zahlen  sind eine endlich erzeugte Gruppe mit Erzeugendensystem .
 Allgemeiner sind alle zyklischen Gruppen endlich erzeugte Gruppen.
 Die Menge der positiven rationalen Zahlen  bildet mit der Multiplikation eine Gruppe, die kein endliches Erzeugendensystem besitzt, also nicht endlich erzeugbar ist. Ein minimales Erzeugendensystem dieser Gruppe bildet die abzählbare Menge der Primzahlen.
 Jede freie Gruppe über einer endlichen, mindestens zweielementigen Menge S ist nicht kommutativ, endlich erzeugt – S ist ein Erzeugendensystem – und abzählbar unendlich.

Literatur
 Serge Lang: Algebra (= Graduate Texts in Mathematics. Bd. 211). Revised 3rd edition. Springer, New York NY u. a. 2002, ISBN 978-0-387-95385-4.

Gruppe (Mathematik)
Kombinatorische Gruppentheorie


text:
Picture post: Shale gas villagers highlight 'threat' to owls
By Ruth Hayhurst on August 9, 2018 • ( 11 Comments )
Owl awareness-raising event outside the IGas shale gas site Springs Road, Misson, 4 August 2018. Photo: Frack Free Misson
Villagers have highlighted what they believe is the threat to five species of owl on land next to the IGas shale gas site at Misson, in north Nottinghamshire.
About 50 people from areas earmarked for fracking in three counties attended a protest and awareness-raising event outside the site entrance.
The event, hosted by Frack Free Misson, coincided with International Owl Awareness Day. It also marked the recent approval of IGas plans to continue construction work at the Springs Road site during the bird breeding season. (DrillOrDrop report)
Rare long-eared owls live and breed 125m away from the exploration site on the Misson Training Area Site of Special Scientific Interest (SSSI). Four other native species, barn, little, short-eared and tawny owls, have also been recorded.
The long-eared owl has become a symbol for Frack Free Misson in its campaign against the fossil fuel industry. Local resident, Julie Field, said:
"Frack Free Misson is fighting to save these beautiful creatures especially the long-eared owl which we are privileged to have at the adjacent SSSI. There are fears that the 24/7 noise, vibration and light will harm the ability of the owls to breed, forage and hunt."
Sheelagh Handy, from Misson, said:
"We are still aiming to stop them and what better day to do this than on International Owl Awareness Day. The owls' habitat will be recklessly damaged by the industry."
Local people said they were concerned that the shale gas site would industrialise the area.
Mary Swindells, who lives a few hundred metres from the site, said:
"I am frightened by what it will do to my way of life – the lights and noise and effects on the local water supply as well as the disturbance to the bats which nest on my property."
Bill Shaw, a longstanding Misson resident, said:
[I am] "dead against fracking and the damage it can cause to the environment. I am here to show support for the people who are working so hard to stop it."
Owl-themed craft event hosted by Frack Free Misson, 4 August 2018. Photo: Frack Free Misson
Frack Free Misson also ran an owl themed craft event in the afternoon on Misson village green. Kath Williamson was there with her family. She said:
"Fracking fractures communities. I am part of this movement to protect the future for my children and grandchildren."
Work resumes
Construction work at Misson stopped at the end of March. But last month Nottinghamshire County Council gave IGas permission to resume the work during the remainder of the bird breeding season between 20 July and 31 August 2018.
A report for IGas, submitted to the council earlier this year, concluded that construction noise was unlikely to disturb owls or other birds. It said:
"predicted construction noise levels in the SSSI were well below the threshold for disturbance to owls contained in USA the Fish and Wildlife Service guidance".
The report concluded:
"There is no reason why construction of the site compound and access
track should not go ahead at any time of year, including during the breeding season."
Categories: protest
Tagged as: construction, disturbance, Frack Free Mission, gas, IGas, long-eared owls, MIsson, Misson Training Area Site of Special Scientific Interest, Nottinghamshire County Council, owls, report, shale, Springs Road, symbol, threat, work
'Government is using Lancashire residents as guinea pigs in a fracking impacts experiment' – doctors
Campaign group begins legal challenge to government planning policy on fracking
nearlydead says:
"predicted construction noise levels in the SSSI were well below the threshold for disturbance to owls contained in USA the Fish and Wildlife Service guidance". Since when have we been subjected to the USA the Fish and Wildlife Service guidance. I must have been on holiday when that was agreed. This is not the USA. We clearly don't have our own regulations let alone Gold Standard regulations, so lets look around the world to see what regulation might help the onshore oil and gas industry to get their own way. Just saying………
hewes62 says:
It's not regulation that is missing, it's a disturbance threshold. See the I Gas report.
Maybe we should go disturb them to write our own, or use available world wide data instead?
If these owls are that sensitive why allow these individuals to disturb them? Injunctions seem required for protection of the owls. Wytch Farm is now an oasis of nature, supporting rare species. Off shore rigs are an oasis for marine species. Let's ban the protestors and increase the oases. Simples.
Jon Mager says:
When did you see and hear an onshore exploration rig working for 24/7 in a UK rural setting? Lighting, generator noise and clanging of pipes reported by neighbours.
Jayne Watson says:
How are the "individuals" disturbing the owls?
John Harrison says:
I wonder how the lighting and noise levels during the drilling period on the site, compare with when the site operated 24/7 as an MOD missile base.
Jon-many times, especially within the largest on-shore oil field in Europe. DYOR, and you will find the answer.
Just to note that the location of the owls is not publicised as the greatest risk is thieves taking eggs and or owls.
So they may anywhere in the reserve, but unlikely to be between the noise monitor and the site.
So it appears there are many threats to owls; let's not needlessly add to it then, eh?
Gledders says:
John H: the owls weren't there when it was an MOD site. They settled after the site closed. The area in which they nest was left undisturbed and uncleared by MOD, and subsequently categorised as a SSSI.


text:
Office of University and Science Communications
You are here: Home › Newsroom › People › Otokar-Fischer-Prize for Tilman …
Otokar-Fischer-Prize for Tilman Kasten
Freiburg literature and cultural studies' scholar becomes the first recipient of an award for outstanding research of Czech literature and culture
Freiburg, Jul 11, 2017
Tilman Kasten. Photo: Ondřej Staněk
An independent initiative of Czech literature scholars, the Institute of Literary Research, has for the first time awarded the Otokar-Fischer-Prize. This year's winner is a literature and cultural studies' scholar at the University of Freiburg, Dr. Tilman Kasten. He received the honor for his 2016 dissertation "Historismuskritik versus Heilsgeschichte – Die Wallenstein-Romane von Alfred Döblin und Jaroslav Durych (Critique of Historicism versus Salvation History – the Wallenstein Novels of Alfred Döblin and Jaroslav Durych)." The chief purpose of the award is to raise awareness of the most significant, German-language research published in Germany in the area of Czech Studies – therefore works on Czech literature, language, visual arts, theater, film architecture, culture and cultural history. Another aim is to strengthen the dialogue between Czech and German Czech Studies.
There are many literary texts about the life of the Bohemian noble and military commander Albrecht von Wallenstein (1583–1634). Tilman Kasten addressed two of these works in his dissertation: Alfred Döblin's "Wallenstein", which was published in 1920, and Jaroslav Durych's 1929 novel "Bloudění", which was published in German with the title "Friedland." Shortly after they appeared, both books were translated into Czech or German respectively and were also received in relation to one another in Germany and Czechoslovakia. The treatments of the character of Wallenstein in both works are viewed as radical rejections of conventional historical narration. While Durych's text depicts a confrontation with national, cultural memory, Döblin pursues radical decontextualization. Furthermore, Durych processed the material with an emphasis on the concept of salvation. "The dissertation demonstrates that both books are not only an expression of a parallel, though also varied, development of the literary genre of the historical novel in Czech and German literature, but at the same time are a fruitful source to follow regarding their reception within the context of German-Czech literary transfer," said the Institute for Literary Research.
Tilman Kasten studied the History of Modern German Literature, West Slavic Philology and European Ethnology at the University of Freiburg. He received his PhD in 2014. From 2013 to 2017 he was a research assistant at the Institut für Volkskunde der Deutschen des östlichen Europa (Institute of European Ethnology of the Germans of Eastern Europe), the director of the Commission for German and Eastern European Ethnology and a co-publisher of the Commission's yearbook. Since April 2017, he has been the research coordinator of Collaborative Research Center 1015 "Leisure – Borders, Temporal and Spatial Character, Practices" at the University of Freiburg.
Dr. Tilman Kasten
Collaborative Research Center "Leisure – Borders, Temporal and Spatial Character, Practices"
Tel.: 0761/203-67707
E-Mail: tilman.kasten@sfb1015.uni-freiburg.de
research & discover
experience & get involved
invent & establish
promote & commit
connect & create
University newspaper
uni'wissen Archive
Expert service for journalists
University Networks
Information Packages
Picture Service
Phone: (+49) 0761 203 4302
Contact Press Relations of the Medical Center – University of Freiburg
Current News of the Medical Center – University of Freiburg
News from University Networks
Quelle: Otokar-Fischer-Prize for Tilman Kasten — Office of University and Science Communications
https://kommunikation.uni-freiburg.de/pm-en/personalia-en/otokar-fischer-prize-for-tilman-kasten ( Feb 01, 2023 )


Bold typefaces, as companions to regular text weights, did not become fashionable until the mid-19th century. Although it is hard to imagine today, the original fonts of Baskerville, Caslon, Garamond and Bodoni did not include bold weights. Bold type grew out of the Industrial Revolution and the birth of advertising. In fact, the first popular bold typefaces were display designs intended to be used at large sizes to grab the reader's attention. It was only later that bold designs were regularly added to typefaces used to set text copy.
Bold typefaces can go by many names: demi bold (sometimes just "demi"), bold, extra bold, and black and ultra. As the names imply, their stroke weights are incremental degrees heavier than the basic roman or medium weight of a typeface. Their primary use in text copy is to provide emphasis or establish a typographic hierarchy that conveys relative ranking of information. In this context, bold weights clarify content.
Headings and subheads can be set in bold type.
Bold weights of type can easily establish priority. Typographic hierarchy is about creating different levels of importance through typeface choice and text arrangement. Used sparingly, different typeface weights (and proportions) can guide the reader through long or complicated documents. Think of the various typeface weights as graphic road signs: a few, well-placed, will help the reader navigate the content. Too many will distract and confuse.
Headings are often set in bold type, as are subheads and page numbers. "Jump Lines" – short messages to the reader at the end of a column, explaining where the text continues –, are also frequently set in bold type. In addition, if used sparingly, bold type on a page adds a touch of graphic diversity to otherwise monotone pages of text copy.
As visual punctuation, bold type is more commanding than italics or a point size change. Because it does stand out, however, too much bold type on a page can be distracting and even disruptive to the reading process. For this reason, italics are normally used in running text when more than a couple of words are to be emphasized.
Some typeface families have relatively subtle gradations in change from one weight to another. In these designs, a jump of two weights may be advisable to create an obvious contrast.
When working on an Apple computer, select heavier weights of typefaces from the font menu, not the style bar. If the font weights are not linked, or if there is no bold font, a digital embolding will result. This looks more like type dipped in chocolate than like a professionally drawn variation on the basic design.
On computers using the Microsoft® Windows® OS, bold typefaces can only be accessed through the style bar or menu.
Jump lines are often set in bold.
Too much bold type is distracting.
Set in Avenir Regular, Medium and Demi.


AASL 4.1.1 - Read, View and listen for pleasure and personal growth.
AASL 4.1.3 - Respond to literature and creative expressions of ideas in various formats and genres.
AASL 4.4.3 - Recognize how to focus efforts in personal learning.
(5) Although readers learn a lesson or value, such as being accountable for actions or accepting cultural, physical, or sexual differences of people, good realistic fiction novels do not dictate specific moral and ethical beliefs. Instead, they challenge readers to learn the importance of moral and ethical behavior by drawing their own conclusions.


text:
#Cancer Cell#Targeted Therapy#Immunotherapy#Renal Cell Carcinoma#Clinical Cancer Research#Ipilimumab#Tfs#Imdc#Harvard Medical School#Checkmate 214#Rcc
Study: Immunotherapy Results in Longer Treatment-Free Survival Than Targeted Therapy in Patients With Renal Cell Carcinoma
By Skylar Kenney, Assistant Editor
pharmacytimes.com
Patients with advanced renal cell carcinoma who were given the combination of nivolumab and ipilimumab demonstrated a significantly longer overall survival than those who received sunitinib. The combination therapy of nivolumab plus ipilimumab resulted in longer treatment-free survival (TFS) over a 42-month period compared to the targeted therapy sunitinib...
www.pharmacytimes.com
Signaling mechanisms in pancreatic cancer cells could provide new target for treatment
Research led by scientists at the UCLA Jonsson Comprehensive Cancer Center provides new insights into molecular "crosstalk" in pancreas cancer cells. The study, published in the journal Cell Reports, identifies vulnerabilities that could provide a target for therapeutic drugs already being studied for several different types of cancer. It was led by Dr. Caius Radu, a UCLA professor of molecular and medical pharmacology, and Dr. Timothy Donahue, a pancreatic cancer surgeon.
CANCER・ 4 DAYS AGO
Study: Intravenous Ketamine Is a Rapid and Robust Treatment for Depression
In a subset of 537 patients receiving the IV therapy across 178 clinics, there was a 54% response rate and 30% remission rate. Study results on outcomes of ketamine intravenous therapy (KIT) show that it a rapid and robust treatment for depression, health care technology company Osmind and Public Benefit Corporation, said in a statement.
HEALTH・ 5 DAYS AGO
Pembrolizumab Yields Significantly Improved Disease-Free Survival in Non–Small Cell Lung Cancer
Patients with stage IB to IIIA non–small cell lung cancer saw an improvement in disease-free survival when treated with pembrolizumab compared with the placebo regardless of PD-L1 expression. Patients with stage IB to IIIA non–small cell lung cancer (NSCLC) who were treated with pembrolizumab (Keytruda) following surgical resection vs...
ophthalmologytimes.com
Renal function could be a predictor for poor treatment response in patients with DMO
Assessment of renal function could help explain the treatment response for patients with diabetic macular oedema. Korean investigators reported that poor kidney function negatively impacts the response to intravitreal bevacizumab injections (Avastin, Genentech Inc.) and intravitreal dexamethasone implantation (Ozurdex, Allergan) in patients with diabetic macular oedema (DMO). Renal function may...
DISEASES & TREATMENTS・ 13 DAYS AGO
oncnursingnews.com
Immunotherapy Approvals Propel the Future of GI Cancer Treatment
Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer. Despite years of negative clinical trials and minimal advancement, frontline immunotherapy regimens are beginning to show significant promise in revamping the treatment landscape...
CANCER・ 12 DAYS AGO
Lymphodepletion Improves Results for Allogenic CAR T-Cell Therapy in ALL
Nitin Jain, MD, discusses the preliminary results of a study investigating allogenic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Nitin Jain, MD, associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses the preliminary results...
When to Use Maintenance Therapy in Metastatic Urothelial Carcinoma
Peter H. O'Donnell, MD, PhD: I've got a couple of juicy questions. Shilpa, the first 1 is about the application of these data. Let's say your patient gets a CR [complete response] with frontline platinum. Maybe you give them gemcitabine and cisplatin, and they get a CR. Are you really going to push them toward maintenance, or maybe the cisplatin has some rate of long-term durable control?
survivornet.com
What Are the Treatment Options for a Multiple Myeloma Patient Who Experiences Their First Relapse After Having Been in Remission and on Maintenance Therapy?
Multiple myeloma is an incurable cancer, which means that at some point during a patient's life, the disease will rear its head again. When the cancer comes back — which it ultimately will — patients should know they have options when it comes to treating relapsed multiple myeloma.
FDA Approves Newest Antibody-Drug Conjugate for Cervical Cancer
Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy. Cervical cancer is a rare type of cancer that originates from the cellular lining of the cervix, representing approximately 0.8% of all new cancer cases and 0.7% of all cancer deaths each year in the United States.1.
Cell Metabolism Could Provide Treatment Target for Diffuse Large B Cell Lymphomas
The metabolic protein SIRT3 reduces the pools of amino acids that cells use to make proteins and otherwise fuel their growth. New research has found that aggressive diffuse large B cell lymphomas (DLBCL) have a specific metabolic vulnerability that could be exploited to trick the cancers into starving themselves, according to investigators at Weill Cornell Medicine and Cornell's Ithaca campus.
Considerations for Checkpoint Inhibitor Maintenance Therapy in Urothelial Carcinoma
Daniel Petrylak, MD: So Barry I think that we're seeing some very interesting data. We know that we're getting a survival median up from the start of first-line therapy of about 26, 27 months. I think that there are certainly some advantages to giving this maintenance therapy in this fashion. One of the advantages of this is that you're not having patients drop out, potentially being lost to follow up, and not receiving their second-line therapy, as we saw in that original slide. Remember, we call this line 1.5. However, the question, of course, is are we subjecting some patients to immune toxicities when they would not have received it? And then how can we better find out who those patients are who relapse? I think that that's really a crucial issue. Generally, checkpoint therapy works better in nodal disease than in visceral disease. So the question, of course, is are you going to get the same benefit? I think this is a huge advantage. By giving it earlier, you don't have those people drop out. Barry, your thoughts?
Study: Survival Rate Has Steadily Increased for Adults with Relapsed Acute Lymphoblastic Leukemia Following Hematopoietic Cell Transplant
The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse. New research by the American Association for Cancer Research (AACR) has found that the 2-year overall survival (OS) rate...
New Study Explores EBNA1 as a Target for Epstein-Barr Virus-Positive Advanced Nasopharyngeal Carcinoma
A phase 2 study is preparing to enroll patients with Epstein-Barr virus-positive advanced nasopharyngeal carcinoma, who will be treated with an investigational EBNA1 inhibitor. A phase 2 study has been initiated by Wistar Institute and Stanford University School of Medicine, to explore treatment with VK-2019, an Epstein-Barr Nuclear Antigen-1(EBNA1) inhibitor, in...
austinnews.net
Study finds high-fibre diet linked to improved response to immunotherapy in melanoma patients
Washington [US] January 9 (ANI): According to a new study by the University of Texas MD Anderson Cancer Centre, melanoma patients who ate more fibre during immunotherapy, survived longer without cancer growth. The findings of the study were published in the journal Science. The benefit was most noticeable in patients...
healthleadersmedia.com
Integrative Services Such As Nutrition Counseling Boost Cancer Patient Survival, Study Finds
Access to integrative healthcare services such as exercise counseling increases a breast cancer patient's odds of survival, a recent study indicates. — Offering integrative oncology services such as nutrition counseling and patient support groups benefits many breast cancer patients, a recentresearch article says. Oncologists rely mainly on conventional medicine...
CAR T-Cell Therapy and BiTE: Two New Approaches to Multiple Myeloma Treatment
Two new immunotherapy treatments, CAR T-cell therapy and BiTE, have recently made waves in the multiple myeloma world. CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is a treatment that genetically engineers a patient's own immune cells to attack cancer cells. BiTE, or bispecific T-cell engager, also uses...
Medagadget.com
B-cell Maturation Antigen (BCMA) Targeted Therapies Market – Increasing Number of Multiple Myeloma is Expected to the Boost Growth of the Market
Multiple myeloma (MM) is a type of blood cancer. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Plasma cells are an important part of the immune system, helping to fight a variety of infections and diseases. MM is a type of blood cancer and characterized by renal failure, low blood counts, hypercalcemia, monoclonal gammopathy, immune suppression, and anemia. Moreover, it remains an incurable disease. As reported by the American Cancer Society, in 2017, more than 30,280 new cases of multiple myeloma will be diagnosed in the United States and over 12,590 people will die from the disease. Furthermore, as reported by the National Center for Biotechnology Information (NCBI), MM represented 8.2% of all blood cancers in 2014 in Africa.
BioMarin reports positive results from Phase 3 gene therapy study in hemophilia A
BioMarin Pharmaceutical (NASDAQ:BMRN) announces positive results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. In the study, Annualized Bleeding Rate (ABR) was significantly reduced by 4.1 treated bleeds per year (p-value <0.0001), or 85% from...
MEDICAL & BIOTECH・ 7 DAYS AGO
BTK Inhibitor Treatment Selection in Waldenström Macroglobulinemia
Bhavesh Shah, RPh, BCOP: There are different BTK [Bruton tyrosine kinase] inhibitors that we have options for. The next question for our pharmacy colleagues is, in Waldenström macroglobulinemia, we have 2 BTK inhibitors in which we've seen significant amount of data. If you look at the NCCN [National Comprehensive Cancer Network] Guidelines, both zanubrutinib and ibrutinib are category 1 recommendations. We'll talk about the pivotal ASPRE trial that recently led to the approval of zanubrutinib for Waldenström. But we know that there are differences in off-targets that these agents have, specifically with zanubrutinib having fewer off-target implications vs ibrutinib. We also know there are implications for toxicity because zanubrutinib probably has fewer off-targets. Maybe we can talk a little about the BTK selectivity and the off-target implications for the 2 agents available for Waldenström.
Good News Network
Breakthrough Using CRISPR to Target Fat Cells in Genetic Study of Obesity
Fat—it is vital for life but too much can lead to a host of health problems. Studying how fat tissue, or adipose, functions in the body is critical for understanding obesity and other issues. But structural differences in fat cells and their distribution throughout the body make doing so...
DISEASES & TREATMENTS・ 9 DAYS AGO


text:
Home » Crime Mar 2022 , Foreign Mar 2022 » African woman held at Mumbai airport with heroin worth Rs 56 crore
African woman held at Mumbai airport with heroin worth Rs 56 crore
Mumbai: An African national was arrested on Monday at Mumbai airport after the customs department seized from her 8 kg of heroin worth Rs 56 crore in the international market, an official said.
The woman was found carrying some white powder, which when examined turned out to be heroin.
A case has been registered under Narcotic Drugs and Psychotropic Substances Act, 1985 and further investigation is underway.
01/03/22 Times of India
Categories: Crime Mar 2022, Foreign Mar 2022


text:
Mount Black Prince may refer to:

 Mount Black Prince (Alberta) in Alberta, Canada
 Mount Black Prince in the Admiralty Mountains of Antarctica


Gaining career experience is critical, yet the process of identifying, applying for, and securing these opportunities can be confusing for both students and parents.
Please join us at the Cohen Career Center as we begin putting these internship pieces together. We will host a panel discussion with William & Mary students who have recently completed a variety of internships, both here in the community and nationally. After the panel discussion, tour the Career Center and learn more about our resources for students. A light reception will follow.
Please RSVP if you would like to attend our panel discussion from 1:00-1:45pm. Feel free to join us at 1:45pm if you are unable to participate in our panel discussion but would like a tour of the Career Center and to learn more about programs and services.


text:
Andrena wuae är en biart som beskrevs av Osamu Tadauchi och Xu 1995. Andrena wuae ingår i släktet sandbin, och familjen grävbin. Inga underarter finns listade i Catalogue of Life.

Källor

Sandbin
wuae


In the luxury preowned market, a lot of online luxury resale platform are organized in the form of consignement marketplace. The main problem is these consignment shop is they only offer a expensive fees and commission on sale.
MODE IN LUXE has the particularity to be one of the rare companies in this market, in France as International, to own in stock the offering products. Indeed, following the example of this consignment stores who is intermediate between the buyers and the sellers, we buy cash the majority of the items we sell. We prefer to own rather to take on consignment. The seller is paid immediately.
We are and remain owner of the majority offering products. We select strictly all the articles for their condition, their rarity or their originality and we garantee the authenticity of all of them. We favor the quality and the exceptional as collectible piece.
You can suggest us yours items and we could buy or sell them for you.
Please to fill out this form and we will answer you as soon as possible.


Seven names include this word. For more information, click on the name in the list.
The Hebrew word for a judge is broader than our English term. It encompasses all three aspects of modern government or rule – judicial, legislative, and corrective. As the Lawgiver, God establishes right and wrong; as God of recompense and God of vengeance, He punishes evil and rewards good; as God of justice, He knows exactly the right settlement for every situation. To say that God is judge incorporates all these functions.
In Israel, justice was understood to reside in leading men rather than in the laws. Correct judgment resides in God.
The Judge (Hashofet) in the Hebrew text of Judges 11:27.
The Judge in the Greek text of James 5:9.
Similar names for God are Righteous judge, Judge of (all) the earth, Judge of Israel, God of justice, Our lawgiver, and, in the New Testament, Righteous Judge and Judge of the living and the dead.